top of page


Independent community pharmacists’ attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder

J Am Pharm Assoc. DOI: 10.1016/j.japh.2023.06.010.

Zalmai RS, Hill LG, Loera LJ, Mosgrove Q, Brown CM.

Medications for opioid use disorder in professional recovery programs in the U.S.: Policies and recommendation patterns

Ment Health Clin. DOI: 10.9740/mhc.2023.06.163.

Murchison ML, Loera LJ, Hill LG.

Research and scholarly methods: Audit studies

J Am Coll Clin Pharm. DOI: 10.1002/jac5.1782

Loera LJ, Hill LG, Evoy KE, Reveles KR.

A wound care and immunization needs assessment for participants of a mobile syringe services program in Austin, Texas.

J Am Pharm Assoc. DOI: 10.1016/j.japh.2022.10.018

Britton TR, Clague MR, Zagorski CM, Hill LG, Loera LJ.

A qualitative exploration of unintentional vs. intentional exposure to fentanyl among people who use drugs in Austin, Texas.

J Am Pharm Assoc. DOI: 10.1016/j.japh.2022.10.005

Cance JD, Bingaman A, Kane H, Hairgrove S, Torrez SB, Buck A, Zagorski CM, Loera LJ, Hill LG.

Opioid harm reduction: A scoping review of physician and system-level gaps in knowledge, education, and practice

Subst Abus. 2022. DOI: 10.1080/08897077.2022.2060423.

Gugala E, Briggs O, Moczygemba LR, Brown CM, Hill LG.

Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states

Drug Alcohol Depend. 2022. DOI: 0.1016/j.drugalcdep.2022.109518.

Hill LG, Loera LJ, Torrez SB, Puzantian T, Evoy KE, Ventricelli DJ, Eukel HN, Peckham AM, Chen C, Ganetsky VS, Yeung MS, Zagorski CM, Reveles KR.

Description and Evaluation of a Pilot Advanced Pharmacy Practice Experience in Addiction Medicine

Am J Pharm Educ. 2022. DOI: 10.5688/ajpe8926

Loera LJ, Hill LG, Zagorski CM, Jermain ML, Tirado CF.

Increasingly powerful opioid antagonists are not necessary

Int J Drug Policy. 2022. DOI: 10.1016/j.drugpo.2021.103457.

Hill LG, Zagorski CM, Loera LJ.

Policies regarding use of medications for opioid use disorder in professional recovery programs: A scoping review.

Subst Abus. 2022. DOI: 10.1080/08897077.2021.2010161

White KM, Hill LG, Perez JC, Torrez SB, Zagorski CM, Loera LJ.

bottom of page